Levodopa/Carbidopa/Entacapone Orion

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Orion, is a dopamine precursor / COMT inhibitor combination presented as an oral tablet for oral use. It is indicated for the treatment of Parkinson's disease and for patients who experience motor fluctuations while on levodopa therapy.

GNH USA supplies Levodopa/Carbidopa/Entacapone Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor fluctuations.

- Parkinson's disease: improves overall motor function and reduces bradykinesia. - Parkinson's disease with motor fluctuations: decreases OFF periods and prolongs ON time. - Early-stage Parkinson's disease: provides symptomatic relief as part of combination therapy.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions. Patients should be monitored for both frequent and serious events.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Neuroleptic malignant syndrome - Severe allergic reactions (rash, angioedema) - Hyperpyrexia or fever of unknown origin

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures.

- Blood pressure monitoring: watch for orthostatic drops, especially after dose initiation. - Renal or hepatic impairment: dose may need adjustment; assess organ function regularly. - Psychiatric assessment: monitor for hallucinations, confusion, or mood changes. - Concomitant dopamine antagonists: avoid abrupt discontinuation to prevent severe withdrawal. - Elderly patients: start at low dose and titrate slowly due to increased sensitivity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block dopamine receptors (e.g., haloperidol): may reduce therapeutic effect. - High‑dose alpha‑adrenergic blockers: can cause severe hypotension.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: may increase risk of serotonin syndrome. - Iron or vitamin B6 supplements: can reduce levodopa absorption; separate dosing by at least 2 hours. - High‑protein meals: may compete with levodopa transport, diminishing efficacy.